je.st
news
Tag: samsung
Samsung SmartThings Hub
2015-11-10 21:02:00| PC Magazine: New Product Reviews
With support for many Z-Wave, Zigbee, and Wi-Fi devices, the Samsung SmartThings Hub is one of the most versatile home automation hubs around.
Samsung SmartThings Hub
2015-11-10 19:04:56| PC Magazine: New Product Reviews
With support for many Z-Wave, Zigbee, and Wi-Fi devices, the Samsung SmartThings Hub is one of the most versatile home automation hubs around.
Spreadtrum WCDMA SoC Platform is Adopted for Samsung Z3 Tizen Smartphone
2015-11-10 11:17:45| Wireless - Topix.net
Samsung Z3 Tizen-based smartphone 5.0" SAMOLED models, designed with Spreadtrum's WCDMA 28nm quad-core SoC platform, feature a 1GB RAM/8GB Storage, a micro SD slot up to 128GB, a built-in battery of 2600mAh, supporting 1080p HD video and an 8 megapixel camera.i 1 2i 1 2 The highly integrated WCDMA platform consists 28nm 1.3GHz quad-core WCDMA/HSPA GSM/GPRS baseband chip SC7730SI, power management chip SC2723S, RF chip SR3532S and Spreadtrum's first 3in1 connectivity chip SC2331S. The SC2331S connectivity chip incorporates Wi-Fi , Bluetooth 4.0 A2DP,LE, and FM RDS solutions with standard peripherals, simplified hardware design and product calibration.
Tags: samsung
platform
adopted
soc
Samsung logs top smartphone sales in 5 m...
2015-11-08 04:07:51| Semiconductors - Topix.net
Korean tech behemoth Samsung Electronics Co. became the top smartphone seller in five major regions of the world in the third quarter of the year except in North America, where its archrival Apple Inc. dominated, a report showed Sunday.
Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
2015-11-05 14:43:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Samsung Bioepis will present new Phase 3 clinical data for three investigational immunology biosimilar candidates at the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) 2015 Annual Meeting in San Francisco, Nov. 7-11. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
meeting
annual
Sites : [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] [196] [197] [198] [199] [200] [201] next »